International treatment guidelines call for molecular diagnostic testing for the detection of EGFR-sensitizing mutations, as an aid to treatment selection for NSCLC patients with non-squamous histology [7,8,9]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.